siRNA knockdown of angiopoietin 2 significantly reduces neovascularization in diabetic rats

References

• Punthakee Z, Goldenberg R, Katz P. Definition, classification and diagnosis of diabetes, prediabetes and metabolic syndrome. Can J Diabetes. 2018;42:S10–S15.
   PubMed Web of Science ®Google Scholar
• Association AD. 2. Classification and diagnosis of diabetes: Standards of medical care in diabetes—2021. Diabetes Care. 2021;44(Supplement 1):S15–S33.
   PubMedGoogle Scholar
• Frank RN. Diabetic retinopathy and systemic factors. Middle East Afr J Ophthalmol. 2015;22(2):151.
   PubMedGoogle Scholar
• Thomas R, Halim S, Gurudas S, et al. IDF diabetes atlas: a review of studies utilising retinal photography on the global prevalence of diabetes related retinopathy between 2015 and 2018. Diabetes Res Clin Pract. 2019;157:107840.
   PubMed Web of Science ®Google Scholar
• Tsai T, Kuehn S, Tsiampalis N, et al. Anti-inflammatory cytokine and angiogenic factors levels in vitreous samples of diabetic retinopathy patients. PLOS One. 2018;13(3):e0194603.
   PubMed Web of Science ®Google Scholar
• Hu B, Cheng S-Y. Angiopoietin-2: development of inhibitors for cancer therapy. Curr Oncol Rep. 2009;11(2):111–116.
   PubMed Web of Science ®Google Scholar
• Das A. Diabetic retinopathy: battling the global epidemic. Invest Ophthalmol Vis Sci. 2016;57(15):6669–6682.
   PubMed Web of Science ®Google Scholar
• Alexander SP, Fabbro D, Kelly E, et al. The concise guide to pharmacology 2019/20: catalytic receptors. Br J Pharmacol. 2019;176(S1):S247–S296.
   PubMedGoogle Scholar
• Wu Q, Xu W-D, Huang A-F. Role of angiopoietin-2 in inflammatory autoimmune diseases: a comprehensive review. Int Immunopharmacol. 2020;80:106223.
   PubMed Web of Science ®Google Scholar
• Fiedler U, Scharpfenecker M, Koidl S, et al. The tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood. 2004;103(11):4150–4156.
   PubMed Web of Science ®Google Scholar
• Mandriota SJ, Pepper MS. Regulation of angiopoietin-2 mRNA levels in bovine microvascular endothelial cells by cytokines and hypoxia. Circ Res. 1998;83(8):852–859.
   PubMed Web of Science ®Google Scholar
• Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997;277(5322):55–60.
   PubMed Web of Science ®Google Scholar
• Jang C, Koh YJ, Lim NK, et al. Angiopoietin-2 exocytosis is stimulated by sphingosine-1-phosphate in human blood and lymphatic endothelial cells. Arterioscler Thromb Vasc Biol. 2009;29(3):401–407.
   PubMed Web of Science ®Google Scholar
• Campochiaro PA. Molecular pathogenesis of retinal and choroidal vascular diseases. Prog Retin Eye Res. 2015;49:67–81.
   PubMed Web of Science ®Google Scholar
• Scharpfenecker M, Fiedler U, Reiss Y, et al. The tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J Cell Sci. 2005;118(Pt 4):771–780.
   PubMed Web of Science ®Google Scholar
• Scholz A, Plate KH, Reiss Y. Angiopoietin-2: a multifaceted cytokine that functions in both angiogenesis and inflammation. Ann N Y Acad Sci. 2015;1347:45–51.
   PubMed Web of Science ®Google Scholar
• Asahara T, Chen D, Takahashi T, et al. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res. 1998;83(3):233–240.
   PubMed Web of Science ®Google Scholar
• Partanen J, Armstrong E, Mäkelä T, et al. A novel endothelial cell surface receptor tyrosine kinase with extracellular epidermal growth factor homology domains. Mol Cell Biol. 1992;12(4):1698–1707.
   PubMed Web of Science ®Google Scholar
• Kim I, Kim J-H, Moon S-O, et al. Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Oncogene. 2000;19(39):4549–4552.
   PubMed Web of Science ®Google Scholar
• Hanahan D. Signaling vascular morphogenesis and maintenance. Science. 1997;277(5322):48–50.
   PubMed Web of Science ®Google Scholar
• Polverini PJ. Angiogenesis in health and disease: insights into basic mechanisms and therapeutic opportunities. J Dent Educ. 2002;66(8):962–975.
   PubMedGoogle Scholar
• Kim J, Park JR, Choi J, et al. Tie2 activation promotes choriocapillary regeneration for alleviating neovascular age-related macular degeneration. Sci Adv. 2019;5(2):eaau6732.
   PubMed Web of Science ®Google Scholar
• Oshima Y, Oshima S, Nambu H, et al. Different effects of angiopoietin-2 in different vascular beds: new vessels are most sensitive. FASEB J. 2005;19(8):963–965.
   PubMed Web of Science ®Google Scholar
• Chen J-X, Zeng H, Reese J, et al. Overexpression of angiopoietin-2 impairs myocardial angiogenesis and exacerbates cardiac fibrosis in the diabetic db/db mouse model. Am J Physiol Heart Circ Physiol. 2012;302(4):H1003–H1012.
   PubMed Web of Science ®Google Scholar
• Peplinski BS, Houston BA, Bluemke DA, et al. Associations of angiopoietins with heart failure incidence and severity. J Cardiac Fail. 2021;27(7):786–795.
   PubMed Web of Science ®Google Scholar
• Hackett SF, Ozaki H, Strauss RW, et al. Angiopoietin 2 expression in the retina: upregulation during physiologic and pathologic neovascularization. J Cell Physiol. 2000;184(3):275–284.
   PubMed Web of Science ®Google Scholar
• Luo KQ, Chang DC. Using a hydrogen-bond index to predict the gene-silencing efficiency of siRNA based on the local structure of mRNA. arXiv. 2017:1710.07413.
   Google Scholar
• O’Keefe EP. siRNAs and shRNAs: Tools for protein knockdown by gene silencing. Mater Methods. 2013;3:197.
   Google Scholar
• Yonezawa S, Koide H, Asai T. Recent advances in siRNA delivery mediated by lipid-based nanoparticles. Adv Drug Deliv Rev. 2020;154–155:64–78.
   PubMed Web of Science ®Google Scholar
• Zudaire E, Gambardella L, Kurcz C, et al. A computational tool for quantitative analysis of vascular networks. PLOS One. 2011;6(11):e27385.
   PubMed Web of Science ®Google Scholar
• Kagami K, Morita H, Onda K, et al. Protective effect of caffeine on streptozotocin‐induced beta‐cell damage in rats. J Pharmacy Pharmacol. 2010;60(9):1161–1165.
   Web of Science ®Google Scholar
• Goyal SN, Reddy NM, Patil KR, et al. Challenges and issues with streptozotocin-induced diabetes – a clinically relevant animal model to understand the diabetes pathogenesis and evaluate therapeutics. Chem Biol Interact. 2016;244:49–63.
   PubMed Web of Science ®Google Scholar
• Eleazu CO, Eleazu KC, Chukwuma S, et al. Review of the mechanism of cell death resulting from streptozotocin challenge in experimental animals, its practical use and potential risk to humans. J Diabetes Metab Disord. 2013;12(1):60.
   PubMedGoogle Scholar
• Wilkin T. The accelerator hypothesis: weight gain as the missing link between type I and type II diabetes. Diabetologia. 2001;44(7):914–922.
   PubMed Web of Science ®Google Scholar
• Chaudhry ZZ, Morris DL, Moss DR, et al. Streptozotocin is equally diabetogenic whether administered to fed or fasted mice. Lab Anim. 2013;47(4):257–265.
   PubMedGoogle Scholar
• Adeghate E, Ponery A. GABA in the endocrine pancreas: cellular localization and function in normal and diabetic rats. Tissue Cell. 2002;34(1):1–6.
   PubMed Web of Science ®Google Scholar
• Samuel VT, Shulman GI. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J Clin Invest. 2016;126(1):12–22.
   PubMed Web of Science ®Google Scholar
• Marangoni MN, Brady ST, Chowdhury SA, et al. The co-occurrence of myocardial dysfunction and peripheral insensate neuropathy in a streptozotocin-induced rat model of diabetes. Cardiovasc Diabetol. 2014;13(1):1–10.
   PubMedGoogle Scholar
• Kudat H, Akkaya V, Sozen A, et al. Heart rate variability in diabetes patients. J Int Med Res. 2006;34(3):291–296.
   PubMed Web of Science ®Google Scholar
• Goldberger JJ, Arora R, Buckley U, et al. Autonomic nervous system dysfunction: JACC focus seminar. J Am Coll Cardiol. 2019;73(10):1189–1206.
   PubMed Web of Science ®Google Scholar
• Shah AS, Vajravelu ME, Bacha F, et al. Heart rate variability and cardiac autonomic dysfunction: prevalence, risk factors, and relationship to arterial stiffness in the treatment options for type 2 diabetes in adolescents and youth (TODAY) study. Diabetes Care. 2019;42(11):2143–2150.
   PubMed Web of Science ®Google Scholar
• Tan Y, Zhang Z, Zheng C, et al. Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. Nat Rev Cardiol. 2020;17(9):585–607.
   PubMed Web of Science ®Google Scholar
• Lee W-S, Kim J. Diabetic cardiomyopathy: where we are and where we are going. Korean J Intern Med. 2017;32(3):404–421.
   PubMed Web of Science ®Google Scholar
• Yu Y, Zou J, Han Y, et al. Effects of intravitreal injection of netrin-1 in retinal neovascularization of streptozotocin-induced diabetic rats. Drug Des Dev Ther. 2015;9:6363–6377.
   PubMed Web of Science ®Google Scholar
• Ueno Y, Iwase T, Goto K, et al. Association of changes of retinal vessels diameter with ocular blood flow in eyes with diabetic retinopathy. Sci Rep. 2021;11(1):1–12.
   PubMed Web of Science ®Google Scholar
• Martínez-Ezquerro JD, Herrera LA. Angiogénesis: VEGF/VEGFRs como blancos terapéuticos en el tratamiento contra el cáncer. Cancerología. 2006;1(1):83–96.
   Google Scholar
• Campochiaro PA. Ocular neovascularization. J Mol Med. 2013;91(3):311–321.
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473(7347):298–307.
   PubMed Web of Science ®Google Scholar
• Adams DD. Autoimmune destruction of pericytes as the cause of diabetic retinopathy. Clin Ophthalmol. 2008;2(2):295–298.
   PubMedGoogle Scholar
• Campochiaro PA, Peters KG. Targeting Tie2 for treatment of diabetic retinopathy and diabetic macular edema. Curr Diab Rep. 2016;16(12):126.
   PubMed Web of Science ®Google Scholar
• Ohashi H, Takagi H, Koyama S, et al. Alterations in expression of angiopoietins and the tie-2 receptor in the retina of streptozotocin induced diabetic rats. Mol Vis. 2004;10:608–617.
   PubMed Web of Science ®Google Scholar
• Akwii RG, Sajib MS, Zahra FT, et al. Role of angiopoietin-2 in vascular physiology and pathophysiology. Cells. 2019;8(5):471.
   PubMed Web of Science ®Google Scholar
• Busik JV, Mohr S, Grant MB. Hyperglycemia-induced reactive oxygen species toxicity to endothelial cells is dependent on paracrine mediators. Diabetes. 2008;57(7):1952–1965.
   PubMed Web of Science ®Google Scholar
• Simon MP, Tournaire R, Pouyssegur J. The angiopoietin-2 gene of endothelial cells is up-regulated in hypoxia by a HIF binding site located in its first intron and by the central factors GATA-2 and Ets-1. J Cell Physiol. 2008;217(3):809–818.
   PubMed Web of Science ®Google Scholar
• Eklund L, Kangas J, Saharinen P. Angiopoietin-Tie signalling in the cardiovascular and lymphatic systems. Clin Sci. 2017;131(1):87–103.
   PubMed Web of Science ®Google Scholar
• Hackett SF, Wiegand S, Yancopoulos G, et al. Angiopoietin-2 plays an important role in retinal angiogenesis. J Cell Physiol. 2002;192(2):182–187.
   PubMed Web of Science ®Google Scholar
• Das A, Fanslow W, Cerretti D, et al. Angiopoietin/tek interactions regulate mmp-9 expression and retinal neovascularization. Lab Invest. 2003;83(11):1637–1645.
   PubMed Web of Science ®Google Scholar
• Okamoto N, Tobe T, Hackett SF, et al. Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am J Pathol. 1997;151(1):281–291.
   PubMed Web of Science ®Google Scholar
• Kelly BD, Hackett SF, Hirota K, et al. Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res. 2003;93(11):1074–1081.
   PubMed Web of Science ®Google Scholar
• Gong C-Y, Lu B, Hu Q-W, et al. Streptozotocin induced diabetic retinopathy in rat and the expression of vascular endothelial growth factor and its receptor. Int J Ophthalmol. 2013;6(5):573–577.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Heier JS, Do DV, et al. The Tie2 signaling pathway in retinal vascular diseases: a novel therapeutic target in the eye. Int J Retin Vitr. 2020;6(1):1–11.
   PubMedGoogle Scholar
• Zhou C-F, Liu M-J, Wang W, et al. miR-205-5p inhibits human endometriosis progression by targeting ANGPT2 in endometrial stromal cells. Stem Cell Res Ther. 2019;10(1):1–13.
   PubMed Web of Science ®Google Scholar
• Hu S, Cao S, Liu J. Role of angiopoietin-2 in the cardioprotective effect of fibroblast growth factor 21 on ischemia/reperfusion-induced injury in H9c2 cardiomyocytes. Exp Ther Med. 2017;14(1):771–779.
   PubMed Web of Science ®Google Scholar
• Rahimi P, Mobarakeh VI, Kamalzare S, et al. Comparison of transfection efficiency of polymer-based and lipid-based transfection reagents. Bratisl Lek Listy. 2018;119(11):701–705.
   PubMed Web of Science ®Google Scholar
• Zhang W, Meng J, Ji Y, et al. Inhibiting metastasis of breast cancer cells in vitro using gold nanorod-siRNA delivery system. Nanoscale. 2011;3(9):3923–3932.
   PubMed Web of Science ®Google Scholar
• Nedorubova I, Bukharova T, Vasilyev A, et al. Comparative study of BMP-2 gene delivery to human adipose tissue-derived mesenchymal stem cells with turbofect and polyethylenimine. IOP Conf Ser Earth Environ Sci. 2021;677(4):042024.
   Google Scholar
• Alagia A, Eritja R. siRNA and RNAi optimization. Wiley Interdiscip Rev RNA. 2016;7(3):316–329.
   PubMed Web of Science ®Google Scholar